Logo image of ECX

ECARX HOLDINGS INC-CL A (ECX) Stock Fundamental Analysis

USA - NASDAQ:ECX - KYG292011031 - Common Stock

2.09 USD
+0.05 (+2.45%)
Last: 10/13/2025, 5:05:44 PM
2.14 USD
+0.05 (+2.39%)
After Hours: 10/13/2025, 5:05:44 PM
Fundamental Rating

2

Overall ECX gets a fundamental rating of 2 out of 10. We evaluated ECX against 81 industry peers in the Automobile Components industry. ECX may be in some trouble as it scores bad on both profitability and health. ECX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ECX has reported negative net income.
ECX had negative earnings in each of the past 5 years.
In the past 5 years ECX always reported negative operating cash flow.
ECX Yearly Net Income VS EBIT VS OCF VS FCFECX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -500M -1B -1.5B

1.2 Ratios

With a Return On Assets value of -24.05%, ECX is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -24.05%
ROE N/A
ROIC N/A
ROA(3y)-29.04%
ROA(5y)-28.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ECX Yearly ROA, ROE, ROICECX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500

1.3 Margins

ECX has a better Gross Margin (86.28%) than 100.00% of its industry peers.
In the last couple of years the Gross Margin of ECX has grown nicely.
ECX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y44.64%
GM growth 5YN/A
ECX Yearly Profit, Operating, Gross MarginsECX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

ECX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ECX has more shares outstanding than it did 1 year ago.
ECX has a worse debt/assets ratio than last year.
ECX Yearly Shares OutstandingECX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
ECX Yearly Total Debt VS Total AssetsECX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

ECX has an Altman-Z score of 5.11. This indicates that ECX is financially healthy and has little risk of bankruptcy at the moment.
ECX's Altman-Z score of 5.11 is amongst the best of the industry. ECX outperforms 87.65% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 5.11
ROIC/WACCN/A
WACC8.29%
ECX Yearly LT Debt VS Equity VS FCFECX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 500M -500M -1B -1.5B

2.3 Liquidity

ECX has a Current Ratio of 0.53. This is a bad value and indicates that ECX is not financially healthy enough and could expect problems in meeting its short term obligations.
ECX's Current ratio of 0.53 is on the low side compared to the rest of the industry. ECX is outperformed by 95.06% of its industry peers.
ECX has a Quick Ratio of 0.53. This is a bad value and indicates that ECX is not financially healthy enough and could expect problems in meeting its short term obligations.
ECX has a worse Quick ratio (0.48) than 92.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.53
Quick Ratio 0.48
ECX Yearly Current Assets VS Current LiabilitesECX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

3

3. Growth

3.1 Past

ECX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.75%.
The Revenue has decreased by -7.79% in the past year.
Measured over the past years, ECX shows a very strong growth in Revenue. The Revenue has been growing by 26.01% on average per year.
EPS 1Y (TTM)-33.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.18%
Revenue 1Y (TTM)-7.79%
Revenue growth 3Y26.01%
Revenue growth 5YN/A
Sales Q2Q%-10.17%

3.2 Future

The Earnings Per Share is expected to grow by 34.01% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -20.26% on average over the next years. This is quite bad
EPS Next Y69.39%
EPS Next 2Y43.82%
EPS Next 3Y34.01%
EPS Next 5YN/A
Revenue Next Year22.55%
Revenue Next 2Y25.96%
Revenue Next 3Y27%
Revenue Next 5Y-20.26%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ECX Yearly Revenue VS EstimatesECX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
ECX Yearly EPS VS EstimatesECX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ECX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 10.74, which indicates a very decent valuation of ECX.
The rest of the industry has a similar Price/Forward Earnings ratio as ECX.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.57, ECX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 10.74
ECX Price Earnings VS Forward Price EarningsECX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ECX Per share dataECX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ECX's earnings are expected to grow with 34.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.82%
EPS Next 3Y34.01%

More info and screens

0

5. Dividend

5.1 Amount

ECX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ECARX HOLDINGS INC-CL A

NASDAQ:ECX (10/13/2025, 5:05:44 PM)

After market: 2.14 +0.05 (+2.39%)

2.09

+0.05 (+2.45%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobile Components
Earnings (Last)08-26 2025-08-26/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners5.37%
Inst Owner Change0%
Ins Owners3.14%
Ins Owner Change0%
Market Cap731.06M
Analysts82.22
Price Target3.76 (79.9%)
Short Float %3.48%
Short Ratio1.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-145.16%
Min EPS beat(2)-234.7%
Max EPS beat(2)-55.62%
EPS beat(4)1
Avg EPS beat(4)-95.87%
Min EPS beat(4)-234.7%
Max EPS beat(4)83.75%
EPS beat(8)2
Avg EPS beat(8)-61.63%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-11.64%
Min Revenue beat(2)-31.55%
Max Revenue beat(2)8.27%
Revenue beat(4)3
Avg Revenue beat(4)-0.37%
Min Revenue beat(4)-31.55%
Max Revenue beat(4)11.59%
Revenue beat(8)5
Avg Revenue beat(8)-8.9%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)15.04%
EPS NY rev (3m)15.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.74
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.62
EYN/A
EPS(NY)0.19
Fwd EY9.31%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.56
BVpS-0.85
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.28%
FCFM N/A
ROA(3y)-29.04%
ROA(5y)-28.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y44.64%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover9.58
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.53
Quick Ratio 0.48
Altman-Z 5.11
F-ScoreN/A
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)112.71%
Cap/Depr(5y)115.33%
Cap/Sales(3y)1.36%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.18%
EPS Next Y69.39%
EPS Next 2Y43.82%
EPS Next 3Y34.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.79%
Revenue growth 3Y26.01%
Revenue growth 5YN/A
Sales Q2Q%-10.17%
Revenue Next Year22.55%
Revenue Next 2Y25.96%
Revenue Next 3Y27%
Revenue Next 5Y-20.26%
EBIT growth 1Y85.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year87.44%
EBIT Next 3Y39.68%
EBIT Next 5Y16.6%
FCF growth 1Y58.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.52%
OCF growth 3YN/A
OCF growth 5YN/A